NIPPON-SHOKUBAI
NIPPON SHOKUBAI CO., LTD. (Headquarters: Osaka, Japan, President: Kazuhiro Noda, hereinafter "Nippon Shokubai")(TOKYO:4114) combined forces with Trevi Systems Inc. (Headquarters: California, USA, CEO: John Webley, hereinafter “Trevi Systems” *1) in the development of the draw solution as a key component in the forward osmosis (hereinafter “FO”) system, which is a next generation system for seawater desalination and water treatment. With $4 million grant from US Department of Energy, Trevi Systems commenced a large scale project to demonstrate the production of fresh water at a volume of 500 m3 per day from seawater using the jointly developed draw solution on the islands of Hawaii in June, 2022 (*2) and completed the data collection in September, 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240216286680/en/
Figure 1 Comparison between RO system and FO system (Graphic: Business Wire)
In recent years, water shortage has become a serious problem in the world, and reverse osmosis (hereinafter “RO”) is widely used in the seawater desalination for agricultural and drinking water use and for treatment of industrial water. The RO system is a technology that involves the pressurization of seawater or wastewater over an RO membrane to remove salts (such as NaCl) and impurities. While this system enables the acquisition of high quality water, the large amount of electric power consumed by the pressurizing pump is considered an issue (Figure 1).
Meanwhile, the FO system is focused on as a means that will resolve this issue. The FO system utilizes the osmosis, which is a natural process and occurs when liquids of differing solute concentrations are separated by a semi-permeable membrane and water moves by the process of osmosis from the solution of lower concentration to that of higher concentration. In the seawater desalination, the FO system utilizes the difference in solute concentration in seawater and draw solution, and the natural osmotic pressure as a result of the draw solution on one side of a FO membrane (a semi-permeable membrane) to pull / transport fresh water from seawater into the draw solution with everything taking place under low pressure and energy conditions (Figure 1). Nippon Shokubai and Trevi Systems developed the draw solution to be separated from the recovered water using low grade thermal heat (Photo 1).
Trevi Systems is a company in the United States which was founded in 2010. Key elements of Trevi Systems’ FO system are the use of retrograde thermolytic solute draw solution and recycling of the draw solute back to the FO membrane (Figure 2). Trevi Systems conducted a pilot test to demonstrate the production of fresh water at a volume of 50 m3 per day from seawater in Middle East (the UAE) in 2016, which confirmed that the use of the FO system was able to reduce electric power consumption to about 1/3 compared to that of the RO system.
However, the improvement in the amount of water production is necessary for the widespread utilization of the FO system at full scale, and the improvement in the function of the draw solution as the key component is crucial for realizing this. Nippon Shokubai and Trevi Systems have successfully developed a draw solution with the capability of improving water production by 30% compared with the previous product. This developed draw solution was used in the demonstration pilot plant (500m3/day) operated by Trevi Systems on the islands of Hawaii (*2).
Key achievements of the project include:
- The fresh water recovery ratio from seawater exceeded 65% surpassing commercial RO systems’ capabilities.
- Electrical energy consumption is 1/3 compared with RO systems.
- Competitive Capital Costs: Demonstrated capital costs competitive with existing RO desalination systems.
Trevi Systems is committed to further expanding the NELHA plant’s capabilities, with plans to increase capacity to over 6,000m3/day at the same site, and showcasing the potential for zero liquid discharge (*3) by the use of brine and brine concentration for mineral recovery.
The FO system is under consideration to be introduced for seawater desalination in areas with high demand for water, such as the Middle East, as well as for brine concentration to achieve zero liquid discharge. Nippon Shokubai will make further efforts to improve the performance and functions of the draw solution with a view toward future expansion of the FO system.
*1: About Trevi Systems
Trevi Systems Inc. is California based company who is a pioneer in forward osmosis technology for sustainable and efficient water desalination and brine concentration. With a commitment to innovation and environmental responsibility, Trevi Systems continues to redefine the possibilities in utilizing forward osmosis and pressurized forward osmosis to deliver clean water and other resources from the most challenging wastewaters.
For more information: https://www.trevisystems.com/
*2: FO seawater desalination project in Hawaii
The FO system by Trevi Systems was adopted in the Sun Shot program by the Department of Energy, USA. An experiment will be conducted to demonstrate the desalination of seawater using the solar heat collection facility owned by the Natural Energy Laboratory of the Hawaii Authority (NELHA).
*3: zero liquid discharge (ZLD)
One of water treatment processes intended to reduce wastewater and produce clean water that is suitable for reuse. ZLD systems purify and recycle virtually all wastewater received.
The press release issued by Nippon Shokubai is here.
The press release issued by Trevi Systems is here.
About NIPPON SHOKUBAI CO., LTD.: Nippon Shokubai utilizes the unique technology to manufacture chemicals such as ethylene oxide, acrylic acids, catalysts, superabsorbent polymers. We use chemistry to make the impossible possible, and offer unprecedented solutions to the world, specifically in Environment & Energy, Electronics & Imaging and Daily Use fields. Our corporate mission is "TechnoAmenity: Providing prosperity and comfort to people and society with our unique technology".
For more information: https://www.shokubai.co.jp/en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240216286680/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India18.9.2025 18:22:00 CEST | Press release
Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/ Sai Life Sciences’ Veterinary APIs Unit in Bidar, India. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies. Making the announcement, Krishna Kanumuri, CEO & Managing Direct
Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 17:45:00 CEST | Press release
Celltrion’s Omlyclo™, the first and only omalizumab biosimilar in Europe, will be commercially available starting in Norway, with subsequent rollouts in European countries Results from the global Phase III clinical trial of Omlyclo™ (CT-P39) for the treatment of chronic spontaneous urticaria (CSU), allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) will be presented at a satellite symposium during the 2025 European Academy of Dermatology and Venereology (EADV) Congress Celltrion highlights the strength of its expanding dermatology portfolio with positive clinical results for CT-P55, a biosimilar candidate referencing secukinumab With the launch of Omlyclo™, Celltrion underscores its commitment to advancing innovative and accessible treatments in immunology and dermatology Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereo
Andersen Consulting tilføjer samarbejdsfirmaet Charter18.9.2025 17:14:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine digitale transformationskapaciteter gennem en samarbejdsaftale med Charter, et canadisk konsulentfirma, der er specialiseret i IT-strategi, managed services og applikationslevering. Charter blev grundlagt i 1997 og leverer teknologiprojekter med en forretningsorienteret tankegang og dyb teknisk ekspertise, herunder inden for IT-rådgivning, cloud-infrastruktur, cybersikkerhed, applikationsudvikling, projektlevering og forretningsarkitektur. Charter hjælper traditionelle virksomheder, offentlige institutioner, tjenesteudbydere og mellemstore kunder med implementering, netværksinfrastruktur og kundeorienterede applikationer – der leveres gennem en livscyklus-tilgang fra strategi til udførelse. "Vores mål hos Charter har altid været at fjerne kompleksiteten fra IT og hjælpe organisationer med at bevæge sig fremad med tillid," siger Kelly Michell, præsident for Charter. "Vores samarbejde med Andersen Consulting gør det muligt for os at bringe vores integrere
Andersen Consulting udvider sit udbud inden for cybersikkerhed og teknologi med tilføjelsen af Move18.9.2025 17:06:00 CEST | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Move, der er en førende virksomhed inden for it-infrastruktur, driftstjenester og digitale løsninger til virksomheder. Move befinder sig i Norge og Sverige. Move blev grundlagt i 1989 og leverer konsulentydelser, it-løsninger og driftstjenester. Virksomheden har ekspertise inden for cybersikkerhed, cloud-løsninger, server- og lagringsløsninger, netværkskommunikation og implementering af AI. Move samarbejder med mellemstore og store virksomheder om at designe, implementere og drive sikre, skalerbare og fremtidssikrede it-miljøer. "Dette samarbejde er en spændende mulighed for at skabe endnu større værdi for vores kunder," siger Roald Sannæs, der er administrerende direktør i Move. "Med vores kompetencer og Andersen Consultings globale rækkevidde og ekspertise kan vi levere mere helhedsorienterede løsninger, der hjælper organisationer med at løse nutidens udfordringer og forudse fremtidens muligheder." "Move har opbygget et godt ren
Setting the Standard: AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’18.9.2025 16:40:00 CEST | Press release
The inaugural ranking by TIME, in partnership with Statista, features AMRA as one of the world’s leading health technology companies that are “driving innovation, enhancing accessibility, and contributing to a more effective and sustainable health care system” AMRA Medical is proud to share its inclusion in the World’s Top HealthTech Companies list, published today by TIME in collaboration with Statista. This recognition positions AMRA among an elite group of global innovators that are leading healthcare transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918372780/en/ AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’ The selection, which comes just one week after celebrating AMRA’s 15 years of progress and innovation within the body composition space, highlights AMRA’s long-standing commitment to becoming a global leader in health informatics. By delivering detailed, reproduc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom